ArticleJournal of cellular and molecular medicine2009
The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth.
Article in Journal of cellular and molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- The intricate interplay between circadian rhythm, androgen signaling, hormone therapy, and cellular senescence in prostate cancer.Cancer metastasis reviews · 2025Review
- The bioactivity of atraric acid as an inducer of cellular senescence in prostate cancer cells is retained by lipophilic derivatives.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Natural compounds targeting nuclear receptors for effective cancer therapy.Cancer metastasis reviews · 2023Review
- Role of Phytotherapy in the Management of BPH: A Summary of the Literature.Journal of clinical medicine · 2023Review
- A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia.Journal of clinical medicine · 2023Review
- Biochemical Properties of Atranorin-Induced Behavioral and Systematic Changes of Laboratory Rats.Life (Basel, Switzerland) · 2022Article
- Article
- Review
- Cell Culture-Based Assessment of Toxicity and Therapeutics of Phytochemical Antioxidants.Molecules (Basel, Switzerland) · 2022Review
- Treatment of Benign Prostatic Hyperplasia by Natural Drugs.Molecules (Basel, Switzerland) · 2021Review
- Review
- Natural and Nature-Derived Products Targeting Human Coronaviruses.Molecules (Basel, Switzerland) · 2021Review
- Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer.Cancers · 2020Review
- Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.Seminars in cancer biology · 2016Review
- Phytotherapy for Benign Prostatic Hyperplasia.Current urology reports · 2016Review
- Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy.Journal of molecular neuroscience : MN · 2016Review
- The natural compound Guttiferone F sensitizes prostate cancer to starvation induced apoptosis via calcium and JNK elevation.BMC cancer · 2015Article
- A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.Molecular endocrinology (Baltimore, Md.) · 2014Article
- Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.Molecular cancer · 2014Article
- NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.Investigational new drugs · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracts from Pygeum africanum are used in the treatment of prostatitis, benign prostatic hyperplasia and prostate cancer (Pca), major health problems of men in Western countries. The ligand-activated human androgen receptor (AR) supports the growth of the prostate gland. Inhibition of human AR by androgen ablation therapy and by applying synthetic anti-androgens is therefore the primary goal in treatment of patients. Here, we show that atraric acid (AA) isolated from bark material of Pygeum africanum has anti-androgenic activity, inhibiting the transactivation mediated by the ligand-activated human AR. This androgen antagonistic activity is receptor specific and does not inhibit the closely related glucocorticoid or progesterone receptors. Mechanistically, AA inhibits nuclear transport of AR. Importantly, AA is able to efficiently repress the growth of both the androgen-dependent LNCaP and also the androgen-independent C4-2 Pca cells but not that of PC3 or CV1 cells lacking AR. In line with this, AA inhibits the expression of the endogenous prostate specific antigen gene in both LNCaP und C4-2 cells. Analyses of cell invasion revealed that AA inhibits the invasiveness of LNCaP cells through extracellular matrix. Thus, this study provides a molecular insight for AA as a natural anti-androgenic compound and may serve as a basis for AA derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists, that can be used for prophylaxis or treatment of prostatic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.